KIMS posts Q3 FY24 consolidated PAT at Rs. 71.84 Cr

KIMS has reported total income of Rs. 609.091 crores during the period ended December 31, 2023

Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg

Gabapentin is indicated for the management of Postherpetic Neuraligia

Roche inaugurates new campus for Digital Centre of Excellence in Pune

The new campus has been designed as an employee-centred experience and ecosystem zone

BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO

An accomplished R&D leader and champion of the application of AI to drug discovery

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom

Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market

Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets

Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg

Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis

Venus Remedies eceives GMP certification from Libya

The certification underscores Venus Remedies Limited's adherence to stringent quality control measures

Pharmatech Associates adds Dr. Praveen Tyle to Board of Trustees

Nethradhama’s conference on ophthalmology sees launch of advanced eye care technologies

The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)